{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:29:36Z","timestamp":1769819376234,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40265-021-01527-9","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T10:03:11Z","timestamp":1620640991000},"page":"945-952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or \u03b2-Thalassaemia"],"prefix":"10.1007","volume":"81","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"1527_CR1","volume-title":"Guidelines for the management of transfusion dependent thalassaemia (TDT)","author":"MD Cappellini","year":"2014","unstructured":"Cappellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd ed. Nicosia (CY): Thalassaemia International Federation; 2014.","edition":"3"},{"issue":"Suppl 3","key":"1527_CR2","doi-asserted-by":"publisher","first-page":"iii57","DOI":"10.1093\/annonc\/mdu180","volume":"25","author":"P Fenaux","year":"2014","unstructured":"Fenaux P, Haase D, Sanz GF, et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii57\u201369.","journal-title":"Ann Oncol."},{"issue":"7","key":"1527_CR3","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3324\/haematol.2020.248955","volume":"105","author":"E Hellstr\u00f6m-Lindberg","year":"2020","unstructured":"Hellstr\u00f6m-Lindberg E, Tobiasson M, Greenberg P. Myelodysplastic syndromes: moving towards personalized management. Haematologica. 2020;105(7):1765\u201379.","journal-title":"Haematologica"},{"issue":"2","key":"1527_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.hoc.2019.10.004","volume":"34","author":"RS Komrokji","year":"2020","unstructured":"Komrokji RS. Luspatercept in myelodysplastic syndromes: who and when? Hematol Oncol Clin N Am. 2020;34(2):393\u2013400.","journal-title":"Hematol Oncol Clin N Am."},{"key":"1527_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: myelodysplastic syndromes (ver 3.2021). 2020. https:\/\/www.nccn.org. Accessed 21 Apr 2021."},{"issue":"9","key":"1527_CR6","first-page":"CD010517","volume":"9","author":"A Sharma","year":"2019","unstructured":"Sharma A, Mathew ME, Puri L. Splenectomy for people with thalassaemia major or intermedia. Cochrane Database Syst Rev. 2019;9(9):CD010517.","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"1527_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/bjh.12694","volume":"164","author":"SB Killick","year":"2013","unstructured":"Killick SB, Carter C, Culligan D, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2013;164(4):503\u201325.","journal-title":"Br J Haematol."},{"issue":"8","key":"1527_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","volume":"133","author":"P Fenaux","year":"2019","unstructured":"Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133(8):790\u20134.","journal-title":"Blood"},{"issue":"6","key":"1527_CR9","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1097\/HS9.0000000000000314","volume":"3","author":"U Germing","year":"2019","unstructured":"Germing U, Oliva EN, Hiwase D, et al. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. Hemasphere. 2019;3(6):e314.","journal-title":"Hemasphere."},{"key":"1527_CR10","unstructured":"European Medicines Agency. Reblozyl\u00ae (luspatercept): EU summary of product characteristics. 2020. https:\/\/www.ema.europa.eu. Accessed 21 Apr 2021."},{"key":"1527_CR11","unstructured":"Celgene Corporation. REBLOZYL\u00ae (luspatercept-aamt): US prescribing information. 2020. https:\/\/www.fda.gov. Accessed 21 Apr 2021."},{"issue":"25","key":"1527_CR12","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1182\/blood-2013-06-511238","volume":"123","author":"R Suragani","year":"2014","unstructured":"Suragani R, Cawley SM, Li R, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine \u03b2-thalassemia. Blood. 2014;123(25):3864\u201372.","journal-title":"Blood"},{"issue":"4","key":"1527_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"R Suragani","year":"2014","unstructured":"Suragani R, Cadena SM, Cawley SM, et al. Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408\u201314.","journal-title":"Nat Med."},{"issue":"7","key":"1527_CR14","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ajh.23732","volume":"89","author":"KM Attie","year":"2014","unstructured":"Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766\u201370.","journal-title":"Am J Hematol."},{"issue":"7","key":"1527_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/psp4.12521","volume":"9","author":"NH Chen","year":"2020","unstructured":"Chen NH, Kassir N, Laadem A, et al. Population pharmacokinetics and exposure-response relationship of luspatercept, an erythroid maturation agent, in anemic patients with \u03b2-thalassemia. CPT Pharmacometrics Syst Pharmacol. 2020;9(7):395\u2013404.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"2","key":"1527_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140\u201351.","journal-title":"N Engl J Med."},{"issue":"10","key":"1527_CR17","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","volume":"18","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Germing U, Gotze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18(10):1338\u201347.","journal-title":"Lancet Oncol."},{"issue":"12","key":"1527_CR18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1182\/blood-2018-10-879247","volume":"133","author":"A Piga","year":"2019","unstructured":"Piga A, Perrotta S, Gamberini MR, et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with \u03b2-thalassemia. Blood. 2019;133(12):1279\u201389.","journal-title":"Blood"},{"key":"1527_CR19","doi-asserted-by":"crossref","unstructured":"Fenaux P, Santini V, Mufti GJ, et al. Effects of luspatercept on serum ferritin in patients (pts) with lower-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) in the phase 3 MEDALIST trial. 2020;25th Congress of the European Haematology Association.","DOI":"10.1016\/S2152-2650(20)30971-X"},{"issue":"Suppl 1","key":"1527_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1182\/blood-2019-123064","volume":"134","author":"P Fenaux","year":"2019","unstructured":"Fenaux P, Mufti GJ, Buckstein R, et al. Assessment of longer-term efficacy and safety in the phase 3, randomized, double-blind, placebo-controlled MEDALIST trial of luspatercept to treat anemia in patients (pts) with revised International Prognostic Scoring System (IPSS-R) very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions [abstract no. 841 plus presentation]. Blood. 2019;134(Suppl 1):841.","journal-title":"Blood"},{"issue":"13","key":"1527_CR21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","volume":"382","author":"MD Cappellini","year":"2020","unstructured":"Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia. N Engl J Med. 2020;382(13):1219\u201331.","journal-title":"N Engl J Med."},{"key":"1527_CR22","unstructured":"Taher A, Viprakasit V, Cappellini MD, et al. Assessment of longer-term efficacy and safety in the phase 3 BELIEVE trial of luspatercept to treat anemia in patients (pts) with \u03b2-thalassemia. 2020;25th Congress of the European Haematology Association."},{"key":"1527_CR23","unstructured":"European Medicines Agency. Reblozyl\u00ae (luspatercept): EPAR - public assessment report. 2020. https:\/\/www.ema.europa.eu. Accessed 21 Apr 2021."},{"issue":"4","key":"1527_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bjhh.2016.09.003","volume":"38","author":"D Langhi Jr","year":"2016","unstructured":"Langhi D Jr, Ubiali EMA, Marques JFC Jr, et al. Guidelines on beta-thalassemia major\u2014regular blood transfusion therapy: Associac\u00b8\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associac\u00b8\u00e3o M\u00e9dica Brasileira\u20142016. Rev Bras Hematol Hemoter. 2016;38(4):341\u20135.","journal-title":"Rev Bras Hematol Hemoter."},{"issue":"2","key":"1527_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136(2):157\u201370.","journal-title":"Blood"},{"issue":"4","key":"1527_CR26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1160\/TH06-05-0267","volume":"96","author":"A Taher","year":"2006","unstructured":"Taher A, Ismaeel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96(4):488\u201391.","journal-title":"Thromb Haemost."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01527-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01527-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01527-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T15:25:13Z","timestamp":1621869913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01527-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1527"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01527-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"21 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Connie Kang and Yahiya Y. Syed are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}